share_log

BeyondSpring's Lead Cancer Drug Protects Bone Marrow Stem Cells Within 24 Hours

BeyondSpring's Lead Cancer Drug Protects Bone Marrow Stem Cells Within 24 Hours

万春医药的抗癌先导药物在24小时内保护骨髓干细胞
Benzinga Real-time News ·  2022/09/13 09:58
  • BeyondSpring Inc (NASDAQ:BYSI) announced data from a poster presentation at the ESMO Congress 2022, including a new analysis from the Phase 2/3 PROTECTIVE-1 and PROTECTIVE-2 trials of plinabulin.
  • Plinabulin, the company's lead asset, is a selective immunomodulating microtubule-binding agent, a potent antigen-presenting cell (APC) inducer being developed as an anticancer agent.
  • Related: BeyondSpring Presents New Data From Lead Asset On Neutropenia In Multiple Myeloma Patients.
  • The data provides evidence of protection of bone marrow granulocyte-monocyte progenitor (GMP) stem cells within 24 hours after chemotherapy based on an evaluation of peripheral immature and mature neutrophil counts.
  • The absolute neutrophil count (ANC) with and without plinabulin was comparable at pre-dose C1D1 (p=0.96) but was significantly higher at 24 hours post-chemo dose with plinabulin vs. control.
  • At 24 hours post-chemo dose, the mean ANC had increased by 3.2 x 109/L with plinabulin, whereas the mean ANC had decreased by 0.55 x 109/L with the control due to the myelosuppressive effect of TAC chemotherapy.
  • Price Action: BYSI shares are down 0.47% at $1.52 on the last check Tuesday.
  • 万春医药纳斯达克(Sequoia Capital：BYSI)宣布了2022年欧洲药品监督管理局大会海报演示中的数据，包括对普利布林2/3期保护性1和保护性2试验的新分析。
  • 普利布林是该公司的主要资产，是一种选择性免疫调节微管结合剂，是一种正在开发的作为抗癌剂的有效抗原提呈细胞(APC)诱导剂。
  • 相关： 万春医药公布了Lead Asset关于多发性骨髓瘤患者中性粒细胞减少症的新数据.
  • 根据对外周血未成熟和成熟中性粒细胞计数的评估，这些数据提供了化疗后24小时内骨髓粒-单核细胞祖细胞(GMP)干细胞保护的证据。
  • 中性粒细胞绝对计数(ANC)在用药前和用药前相似(p=0.96)，但化疗后24小时用药组明显高于对照组。
  • 在化疗后24小时，平均ANC增额普利布林3.2×109/L，而平均ANC减少由于TAC化疗的骨髓抑制作用，与对照组相比增加0.55×109/L。
  • 价格行动：比亚迪股价周二尾盘下跌0.47%，至1.52美元。
声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发